1. RAS as an oncogene

2. The undruggable RAS

3. KRAS G12C as a specific exception

4. Daroxonrasib as a pan RAS(On) inhibitor

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Wang-Gillam A , et al. Eur J Cancer. 2019;108:78-87. doi:10.1016/j.ejca.2018.12.007

2.           O’Reilly EM  et al. N Engl J Med. Published online May 31, 2026. doi:10.1056/NEJMOA2605555

3.           Cregg J et al. J Med Chem. 2025;68(6):6041-6063. doi:10.1021/ACS.JMEDCHEM.4C02313/

4.           Fakih MG et al.  Engl J Med. 2023;389(23):2125-2139. doi:10.1056/NEJMOA2308795

5.           de Langen AJ, et al. The Lancet. 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-0

6.           Cox AD et al. Nat Rev Drug Discovery 2014 13:11. 2014;13(11):828-851. doi:10.1038/nrd4389

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.